However, while the clinical significance of TILs in BRAF-mutant melanomas remains largely unknown, the immunomodulatory effects linked to BRAF-targeted therapy–leading to increased expression of melanoma antigens and a more favorable tumor microenvironment—indicate that this feature may hold particular importance in the therapeutic setting [87]. This evidence concerns the gene BRAF and melanoma.